CY1121331T1 - Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4 - Google Patents

Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4

Info

Publication number
CY1121331T1
CY1121331T1 CY20191100051T CY191100051T CY1121331T1 CY 1121331 T1 CY1121331 T1 CY 1121331T1 CY 20191100051 T CY20191100051 T CY 20191100051T CY 191100051 T CY191100051 T CY 191100051T CY 1121331 T1 CY1121331 T1 CY 1121331T1
Authority
CY
Cyprus
Prior art keywords
cxcr4
disclosure
maligrants
hematological
treatment
Prior art date
Application number
CY20191100051T
Other languages
English (en)
Inventor
Michelle R. Kuhne
Chin Pan
Josephine M. Cardarelli
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1121331T1 publication Critical patent/CY1121331T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει ανθρώπινα μονοκλωνικά αντισώματα που δεσμεύονται συγκεκριμένα σε CXCR4 με υψηλή συγγένεια. Αυτή η αποκάλυψη παρέχει επίσης και μέθοδο για αγωγή υποκειμένου που προσβάλλεται με ένα εκφράζοντα CXCR4 καρκίνο, ειδικότερα μια αιματολογική κακοήθεια όπως είναι το πολλαπλό μυέλωμα, η οξεία μυελοειδής λευχαιμία ή το λέμφωμα του μη-Hodgkin, που περιλαμβάνει χορήγηση στο υποκείμενο θεραπευτικώς αποτελεσματικής ποσότητας φαρμακευτικής σύνθεσης που περιλαμβάνει αντίσωμα αντι-CXCR4 της αποκάλυψης. Η αποκάλυψη παρέχει περαιτέρω ένα κιτ για αγωγή ενός καρκίνου σε ένα υποκείμενο που περιλαμβάνει μια δόση ενός αντισώματος αντι-CXCR4 και οδηγίες για χρήση του αντισώματος αντι-CXCR4 στις θεραπευτικές μεθόδους της αποκάλυψης.
CY20191100051T 2011-11-09 2019-01-15 Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4 CY1121331T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (1)

Publication Number Publication Date
CY1121331T1 true CY1121331T1 (el) 2020-05-29

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100051T CY1121331T1 (el) 2011-11-09 2019-01-15 Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4

Country Status (23)

Country Link
US (2) US10428151B2 (el)
EP (1) EP2776032B1 (el)
JP (1) JP6541350B2 (el)
KR (1) KR102024957B1 (el)
CN (1) CN104039320B (el)
AU (1) AU2012335553B2 (el)
BR (1) BR112014011144A2 (el)
CA (1) CA2855155A1 (el)
CY (1) CY1121331T1 (el)
DK (1) DK2776032T3 (el)
EA (1) EA026153B1 (el)
ES (1) ES2705001T3 (el)
HR (1) HRP20182183T1 (el)
HU (1) HUE043001T2 (el)
IL (1) IL232517B (el)
LT (1) LT2776032T (el)
MX (1) MX357100B (el)
PL (1) PL2776032T3 (el)
PT (1) PT2776032T (el)
RS (1) RS58102B1 (el)
SG (1) SG11201401386XA (el)
SI (1) SI2776032T1 (el)
WO (1) WO2013071068A2 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665239A1 (en) * 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
EP3044338B1 (en) * 2013-09-12 2021-11-24 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
ES2742079T3 (es) 2013-11-06 2020-02-13 Bristol Myers Squibb Co Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
WO2015085075A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
KR20240042192A (ko) * 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
EP3102607B1 (en) * 2014-02-06 2018-08-22 Yeda Research and Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
CN106794219A (zh) * 2014-02-19 2017-05-31 北京迈康斯德医药技术有限公司 趋化因子受体拮抗体及其联合疗法
US10538596B2 (en) * 2015-01-09 2020-01-21 Adalta Limited CXCR4 binding molecules and methods of use thereof
AU2016249395B2 (en) 2015-04-17 2022-04-07 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-PD-1 antibody and another antibody
MX2017015811A (es) 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
ES2907486T3 (es) * 2015-09-24 2022-04-25 Univ North Carolina Chapel Hill Métodos y composiciones para reducir metástasis
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
KR102033920B1 (ko) * 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
ES2912131T3 (es) 2016-05-20 2022-05-24 Biohaven Therapeutics Ltd Uso de agentes moduladores del glutamato con inmunoterapias para tratar el cáncer
JP2019528241A (ja) * 2016-06-16 2019-10-10 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ インターフェロンレベルを低下させるのに有用な化合物
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN110234352A (zh) * 2017-01-31 2019-09-13 Msm蛋白质技术公司 抗cxcr4抗体
MX2019009821A (es) * 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
IL269026B1 (en) 2017-03-31 2024-08-01 Bristol Myers Squibb Co Anti-PD-1 antibodies for the treatment of tumors in patients with a high tumor mutational burden (TMB)
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
US20210162009A1 (en) * 2017-12-08 2021-06-03 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
JP7561631B2 (ja) 2018-03-13 2024-10-04 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラ・パス 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
JP2021519298A (ja) 2018-03-27 2021-08-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 紫外線シグナルを使用した力価のリアルタイムモニタリング
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
JP2022532930A (ja) 2019-05-23 2022-07-20 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
KR20230080460A (ko) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
US20240294651A1 (en) * 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
WO2005024015A1 (en) 2003-09-04 2005-03-17 Medarex, Inc. Expression vector
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
KR101512503B1 (ko) * 2006-02-28 2015-04-15 파르마 마르 에스.에이. 개선된 항종양 치료
CA2665239A1 (en) * 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
WO2010135468A1 (en) 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
BR112013003823A2 (pt) 2010-08-20 2016-06-28 Cerulean Pharma Inc conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados

Also Published As

Publication number Publication date
HUE043001T2 (hu) 2019-07-29
IL232517A0 (en) 2014-06-30
ES2705001T3 (es) 2019-03-21
US20140322208A1 (en) 2014-10-30
MX2014005267A (es) 2014-07-28
CA2855155A1 (en) 2013-05-16
AU2012335553B2 (en) 2017-09-21
IL232517B (en) 2018-05-31
CN104039320B (zh) 2019-10-15
EA201490957A1 (ru) 2014-08-29
JP6541350B2 (ja) 2019-07-10
US20200231683A1 (en) 2020-07-23
PT2776032T (pt) 2019-01-21
US10428151B2 (en) 2019-10-01
RS58102B1 (sr) 2019-02-28
WO2013071068A2 (en) 2013-05-16
SI2776032T1 (sl) 2018-12-31
PL2776032T3 (pl) 2019-03-29
HRP20182183T1 (hr) 2019-02-22
BR112014011144A2 (pt) 2017-05-16
MX357100B (es) 2018-06-26
CN104039320A (zh) 2014-09-10
SG11201401386XA (en) 2014-10-30
EA026153B1 (ru) 2017-03-31
KR20140093945A (ko) 2014-07-29
WO2013071068A3 (en) 2013-07-18
LT2776032T (lt) 2018-12-10
DK2776032T3 (en) 2019-02-04
EP2776032B1 (en) 2018-10-17
AU2012335553A1 (en) 2014-07-03
KR102024957B1 (ko) 2019-09-24
JP2014533279A (ja) 2014-12-11
EP2776032A2 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
CY1121331T1 (el) Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4
PH12019502070A1 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
EA201691858A1 (ru) Композиции антител для лечения опухолей
NZ769968A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
MD3353212T2 (ro) Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EA201590866A1 (ru) Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
CY1115374T1 (el) Αναστολεiς μετ για ενiσχυση αποτελεσματικoτητας ραδιοθεραπειας
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA202090303A2 (ru) Композиции антител для лечения опухолей
EA202092151A1 (ru) Антитела
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
AR110165A1 (es) Anticuerpos anti-met, moléculas biespecíficas de unión a antígeno que se unen a met, y métodos de uso
EA201990258A1 (ru) Антитела к tim-3
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores